Heterogeneity of chemosensitivity of esophageal and gastric carcinoma

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 397-403

  Mercer, Stuart J ^a,b   Somers, Shaw S ^b   Knight, Louise A ^a   Whitehouse, Pauline A ^a   Sharma, Sanjay ^a   Di Nicolantonio, Federica ^a   Glaysher, Sharon ^a   Toh, Simon ^b   Cree, Ian A ^a,c  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b Academic Department of Surgery   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Chemosensitivity; Esophageal cancer; Gastric cancer; Luciferase

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; TREOSULFAN;

ADULT; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ASSAY; DRUG POTENTIATION; DRUG SENSITIVITY; ENDOSCOPIC BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; IC 50; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR BIOPSY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0043128678     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00002     Document Type: Article

References (18)

1. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion of 5-fluorouracil (ECF). Ann Oncol 1994; 5:609-616.
2. Bamias A, Hill ME, Cunningham D, Norman AR, Ahmed FY, Webb A, et al. Epirubicin, cisplatin and protracted infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer 1996; 77:1978-1985.
3. Niederhuber JE. Neoadjuvant therapy. Ann Surg 1999; 229:309-312.
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Hagland U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
6. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-1733.
7. Geh JI, Glynne-Jones R, Kwok QS, Banerji U, Livingstone JI, Townsend ER, et al. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin Oncol 2000; 12:182-187.
8. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs 1997; 8:541-548.
9. Bosanquet AG. In vitro drug sensitivity testing for the individual patient and adjunct to current methods of treatment choice. Clin Oncol 1993; 5:195-197.
10. Bellamy WT. Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 1992; 44:690-708.
11. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, et al. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 1999; 10:437-444.
12. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
13. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998; 9:51-57.
14. Hunter EM, Sutherland LA, Cree IA, Subedi AM, Hartmann D, Linder D, Andreotti PE. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anticancer Drugs 1994; 5:171-176.
15. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection in gastric cancer. Ann Surg 1999; 220:303-308.
16. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P. Prospective randomised trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI-5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996-2004.
17. Allum W, Griffin S, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50(suppl 5):1-23.
18. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87:227-253.